AbbVie (ABBV) Thursday said it has submitted Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of glabellar lines.
The BLA submission is supported by data from two pivotal Phase 3 studies evaluating TrenibotE for the treatment of moderate to severe glabellar lines and a Phase 3 open-label safety study. All primary and secondary endpoints of the Phase 3 studies were met, with a rapid onset of action as early as 8 hours after drug administration and shorter duration of effect of 2-3 weeks.
If approved, TrenibotE will be the first neurotoxin of its kind available to patients, the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.